Germline mutations in BRCA1 and BRCA2 are responsible for a large proportion of hereditary breast and ovarian cancers. Soon after the identification of both genes in the mid-1990s, investigators set out to develop mouse models for the associated disease. Whereas conventional Brca1 and Brca2 mouse mutants did not reveal a strong phenotype in a heterozygous setting, most homozygous mutations caused embryonic lethality. Consequently, development of mouse models for BRCAassociated tumorigenesis required the generation of tissuespecific conditional knockout animals. In this review, we give an overview of the conventional and the conditional mouse models of BRCA1 and BRCA2 deficiency generated over the last decade, as well as the contribution of these models to our understanding of the biological and molecular functions of BRCA1 and BRCA2. The most advanced mouse models for BRCA1-and BRCA2-associated tumorigenesis mimic human disease to the extent that they can be used in studies addressing clinically relevant questions. These models will help to resolve yet unanswered questions and to translate our increasing knowledge of BRCA1 and BRCA2 biology into clinical practice.
Introduction
Breast cancer is the most common malignancy in women of the Western world, affecting up to 10% of the female population (Alberg and Helzlsouer, 1997 ). An estimated 5% of all breast cancers is ascribed to hereditary predisposition. Intensive research in the early 1990s has led to the identification of two major breast cancer susceptibility genes, BRCA1 Miki et al., 1994) and BRCA2 Tavtigian et al., 1996) . Individuals carrying mutations in one allele of either BRCA1 or BRCA2 have a lifetime risk of up to 80% for developing breast cancer and also display increased risk for ovarian cancer (B40% for BRCA1 mutation carriers and B20% for BRCA2 carriers, respectively) (Narod and Foulkes, 2004) . In most breast cancers arising in BRCA1/2 carriers, inactivation of the wild-type allele has occurred by means of loss of heterozygosity, thus abolishing normal protein expression (Smith et al., 1992; Collins et al., 1995) . BRCA1 tumors show a rather uniform tumor type of high-grade invasive ductal carcinomas, which are usually estrogen receptor (ER) and HER2/neu negative (Chappuis et al., 2000; Phillips, 2000) . These properties are reminiscent of 'triple-negative' (ER-, progesterone receptor (PR)-and HER2/neu-negative) basal-like sporadic breast cancers (Livasy et al., 2006) . Indeed, cluster analysis of gene expression data from human breast cancers revealed strong similarity between BRCA1-mutated tumors and basal-like breast cancers (Sorlie et al., 2003) . BRCA2 deficient tumors, on the other hand, show larger variety in histological classification and are not easily distinguished from the overall spectrum of sporadic tumors. While parity in the general population has been associated with decreased breast cancer risk, parity per se was not found to influence risk in BRCA1 mutation carriers, although multiparity did seem to protect as well. For BRCA2, data suggest that increasing parity is associated with increased risk of breast cancer. BRCA2-mutation carriers also have an increased risk of developing pregnancy-associated breast cancer (Cullinane et al., 2005) .
Conventional Brca1 and Brca2 mutants
Following identification of the BRCA1 and BRCA2 breast cancer genes in humans, investigators sought to recapitulate the effects of these genetic lesions in mouse models. Several groups have generated a range of conventional Brca1 and Brca2 knockout mice with mutations in different portions of the genes (see Figures 1 and 2 ). Somewhat disappointingly, none of these mouse mutants showed a strong tumor predisposing phenotype in a heterozygous setting. When bred to homozygosity, most Brca1 and Brca2 mouse mutants displayed severe embryonic lethal phenotypes. Although these traits have hindered in vivo analysis of tumor suppressor functions of Brca1 and Brca2, conventional mouse mutants have provided valuable insight into their biological roles.
Functional clues
Soon after the generation of Brca1 and Brca2 mouse mutants, it was acknowledged that the embryonic lethality of Brca1-deficient mice closely resembled the phenotype of mouse mutants of Rad51, a homologue of the bacterial RecA protein known to be involved in DNA damage repair (Lim and Hasty, 1996) . Subsequently, Rad51, Brca1 and Brca2 proteins were shown to have similar expression patterns during mouse embryogenesis (Lane et al., 1995; Marquis et al., 1995; Sharan et al., 1997; Blackshear et al., 1998) and during cell-cycle progression (Rajan et al., 1996; Chen et al., 1997) . In addition, Brca1, Brca2 and Rad51 were found to co-localize in nuclear dot patterns (Scully et al., 1997; Chen et al., 1998) and to interact with each other (Scully et al., 1997; Sharan et al., 1997; Chen et al., 1998) , suggesting a role for the BRCA proteins in DNA-damage repair. This notion was supported by the observation that Brca-deficiency results in chromosomal instability and increased sensitivity to DNA-damaging agents in cultured mouse cells (Sharan et al., 1997; Patel et al., 1998; Shen et al., 1998; Tutt et al., 1999) and in living animals (Tutt et al., 2002) . These phenotypes were subsequently attributed to defects in repair of doublestrand breaks (DSBs) by homologous recombination (HR) (Moynahan et al., 1999 (Moynahan et al., , 2001 Xia et al., 2001) .
Whereas initial studies in Brca1 and Brca2 mouse mutants have highlighted similarities between both proteins, other research efforts have also revealed clear differences (Venkitaraman, 2002 ). BRCA1 appears to be more of a signal integrator, linking together sensors and response mechanisms of several types of DNA damage. In contrast, BRCA2 is thought to be more directly involved in homology-directed DSB repair, as it mediates the formation of a RAD51-DNA nucleoprotein filament that catalyzes strand invasion during HR (Pellegrini and Venkitaraman, 2004) .
For BRCA1, a wealth of data describes many interactions with other proteins, as well as many Figure 1 Conventional and conditional Brca1 mutant alleles generated to date. Exon compositions for the predicted splice products are indicated, including the Brca1-D11 splice variant and the -for mice putative -Brca1-IRIS product. A w indicates that the predicted transcript contains a premature stop, resulting from a frame shift. In that case only the exons encoding the (predicted) truncated protein product are indicated. The bottom panel shows all BRCA1 splice variants known to exist in humans and mice. BRCA1 lacks exon 4, which had been erroneously identified during the initial cloning of the BRCA1 gene (Miki et al., 1994) . EL: embryonic lethality day.
Mouse models of BRCA1/2 deficiency B Evers and J Jonkers functions besides the involvement in the maintenance of genetic stability. Thus, apart from DNA repair, functions have been described for BRCA1 in all phases of the cell cycle (Deng, 2006) , transcription (Lane, 2004) and DNA decatenation (Lou et al., 2005) . Studies with the Brca1 mouse mutants -or primary cells derived thereofhave revealed several distinct activities of Brca1, including its potential roles in the G2-M cell cycle and spindle assembly checkpoints (Xu et al., 1999b; Wang et al., 2004a) , maintenance of telomere integrity (McPherson et al., 2006) and transcriptional repression of unsynapsed chromosomal regions during meiosis (Turner et al., 2004) . Interesting with respect to the gender specificity observed in BRCA-associated cancers is the reported role for BRCA1 in maintenance of X-chromosome inactivation (Ganesan et al., 2002) . Recent studies have suggested that also BRCA2 may, in addition to its role in HR, have other functions in for example transcriptional regulation (Shin and Verma, 2003) . Notably, primary mouse embryonic fibroblasts derived from hypomorphic Brca2 mutants have provided important clues regarding possible roles of Brca2 in stabilization of stalled DNA replication forks (Lomonosov et al., 2003) and cytokinesis (Daniels et al., 2004) .
The BRCA paradox The developmental failure of both Brca1-and Brca2-deficient animals was mainly ascribed to a proliferation defect (Hakem et al., 1996; Liu et al., 1996; Ludwig et al., 1997; Suzuki et al., 1997) . This striking observation introduced a paradox in the biology of BRCA1 and BRCA2. Whereas BRCA-deficient tumor cells proliferate rapidly in situ, cells in developing Brca-deficient embryos suffer from a proliferation defect. Although this paradox is still unresolved, part of it might be explained by the genetic interactions between BRCA1/2 and the p53 pathway. Growth-arrested Brca1-and Brca2-deficient embryos showed activation of the Cdkn1a gene encoding the cyclin-dependent kinase (cdk) inhibitor p21, a p53 downstream target known to function in the G1-S cell cycle checkpoint (Hakem et al., 1996; Suzuki et al., 1997) .
To investigate the role of p53 and p21 in Brca-associated proliferation arrest, compound mutant animals lacking both Brca1/2 and p53 or p21 were produced by cross-breeding Ludwig et al., 1997) . Whereas embryonic survival of Brca1 mutant embryos was partially rescued in a p53-or p21-deficient background, rescue of Brca2 knockout animals by disruption of p53 was less clear. Together, these results indicate that in addition to p53 other factors play a role in the proliferation defect of Brca1-or Brca2-deficient embryos.
Genotype-phenotype correlations
As shown in Figures 1 and 2 , the various Brca1 and Brca2 mouse mutants display large phenotypic Figure 2 Conventional and conditional Brca2 mutant alleles generated to date. The exon composition of the predicted splice product from the mutant allele is indicated. A w indicates that the predicted transcript contains a premature stop, resulting from a frame shift.
In that case only the exons encoding the (predicted) truncated protein product are indicated. BRC repeats that are still encoded by the predicted transcript are indicated. EL: embryonic lethality day.
Mouse models of BRCA1/2 deficiency B Evers and J Jonkers variation. Viability and life span differ considerably between models, as did the rescue of embryonic lethality on a p53-null background. Indeed, p53-nullizygosity results in extensive phenotypic rescue of hypomorphic Brca1 mutants (Cressman et al., 1999; Xu et al., 2001; Cao et al., 2003) , but only delays embryonic lethality of Brca1-null mutants Ludwig et al., 1997) . Apart from differences in targeted mutations in Brca1 or Brca2, genetic background differences between the various Brca1 and Brca2 mutant mouse strains are likely to play an important role in the phenotypic differences between the published models.
Truncated proteins
Both Brca1 mouse mutants that are predicted to fail to produce Brca1 protein (i.e. Brca1 ex2 , Brca1
5À6
) die around E7.5-9.5 when bred to homozygosity (see Figure 1) . Embryonic lethality in these Brca1 null models is characterized by reduced cell proliferation without signs of increased apoptosis (Hakem et al., 1996) . Embryonic lethality is also observed in the Brca1
1700T model, carrying a C-terminal truncating mutation that removes the second BRCT repeat . Compared to the Brca1 null models, however, homozygous Brca1
embryos show a delayed embryonic lethality marked by continued cell proliferation and differentiation until an apoptotic response is activated around E9.5-10.5. These data suggest that C-terminal truncating Brca1 mutations may have different effects on normal cell function than Brca1-null mutations.
Phenotypic differences are also found for the different Brca2 mutations generated to date (see Figure 2 ). Based on these differences, it was previously suggested that embryos carrying Brca2 mutations that did not encode any BRC repeat could not survive, whereas embryos carrying Brca2 mutations that encoded at least three BRC repeats were partially viable (Connor et al., 1997; Friedman et al., 1998; McAllister et al., 2002) . This, however, appears not to be the case for the embryonic lethal Brca2 tm1Mhun mutation, which encodes a truncated protein with four BRC repeats (Yan et al., 2004) .
Although several Brca1 and Brca2 mutations have been described as resulting in truncating alleles ( Figures  1 and 2 ), in most cases the presence of a truncated protein has not been demonstrated. Some of these mutations could be effectively null alleles if the mRNA or protein is unstable. Nevertheless, the large phenotypic variation of the various mouse mutants predicts that also different human BRCA1 or BRCA2 germline mutations will have different effects on normal cell function and tumor predisposition. Additional mouse models mimicking defined germline mutations are needed to address this important issue. The first 'humanized' mouse models have already been generated via introduction of a BAC transgene containing the human BRCA1 gene into homozygous Brca1 knockouts. Whereas embryonic lethality was completely rescued by wild-type BRCA1 (Chandler et al., 2001) , no rescue was observed for a human BRCA1 C64G allele with a missense mutation in the RING finger domain (Yang et al., 2003) .
Alternative splice products An important and often underappreciated aspect that has complicated proper interpretation of the Brca1 mutant models, is the fact that Brca1 transcripts are subject to alternative splicing. As a result of this, interpretations of targeted mutations in Brca1 should not only take into account the effects on the full-length transcript, but also on all possible splice variants. For humans, several alternative splice products have been described (Lu et al., 1996; Thakur et al., 1997; Wilson et al., 1997; Xu et al., 1997; Elshamy and Livingston, 2004; Fortin et al., 2005) . Of all splice variants, only the BRCA1-D11 and BRCA1-IRIS variants have been functionally analyzed to date (Huber et al., 2001; Elshamy and Livingston, 2004) . The Brca1-D11 splice variant is conserved in mice (Mixon et al., 2000) , whereas existence of a rodent Brca1-IRIS splice variant is still undetermined.
Several Brca1 mutations that encode truncated versions of the full-length protein could, at least in theory, still lead to the production of Brca1-D11 splice variants (see Figure 1) , and the increased viability of some of the homozygous mouse mutants strongly suggests that these alternative splice products have a biological function. Indeed, similar to full-length Brca1, Brca1-D11 is expressed in a cell-cycle regulated manner and localizes to discrete nuclear foci, despite the fact that this splice product lacks the nuclear localization signals of full-length Brca1. DNA damage-induced Brca1 phosphorylation and Rad51 focus formation, on the other hand, were severely impaired in cells that only express Brca1-D11 (Huber et al., 2001) .
Also Brca1-IRIS may have distinct biological activities, as it is capable of stimulating DNA synthesis, presumably through its interaction with prereplication complexes (Elshamy and Livingston, 2004) . The fact that full-length BRCA1 and BRCA1-IRIS are expressed from different promoters raises the interesting possibility that functions of Brca1 towards tumor suppression and embryonic development might reside on different locations in the gene. Indeed, the only Brca1 deletion mutant with an intact hypothetical Brca1-IRIS coding unit does not suffer from a proliferation defect, yet dies at E10.5 due to apoptosis . Further investigation of these exciting new aspects of BRCA1 biology will help to dissect the different functions exerted by distinct BRCA1 splice variants.
Genetic background effects
Several lines of evidence point towards a strong influence of modifier genes on survival of Brca1-and Brca2-deficient animals. Embryonic survival of a lethal Brca2 mutation increased significantly from embryonic day E8.5 on a 129 background to E10.5 on a BALBc background (Bennett et al., 2000) , and postnatal viability of two truncating Brca2 mutations was significantly increased for homozygous mutant mice generated in mixed 129/B6/DBA or 129/MF1 backgrounds compared to 129/B10 or 129/129 genetic backgrounds (Connor et al., 1997; Friedman et al., 1998) . Likewise, embryonic lethality of a hypomorphic Brca1 mutation (which still encodes for Brca1-D11) was completely rescued when the mixed 129/B6 mice were backcrossed onto 129/Sv or outcrossed using MF1 (Ludwig et al., 2001a) . Obviously, it would be interesting to perform backcross experiments in combination with wholegenome scanning studies in the mouse, in order to map and eventually identify modifier genes that affect embryonic lethality of Brca1 and Brca2 mutants. Provided that similar mechanisms mediate viability of Brca-deficient embryos and survival of BRCA-deficient tumor cells, such genes might form interesting therapeutic targets.
Tumor predisposition
Whereas most Brca1 and Brca2 mouse mutants were embryonic lethal when bred to homozygosity, some gave rise to sub-Mendelian ratios of viable offspring. Viable Brca1
Tr/Tr mutants, encoding the Brca1-D11 splice variant, were found to be tumor-prone, although only 12 out of 92 neoplasms were mammary tumors (Ludwig et al., 2001a) . A bias towards lymphoid and sarcomatoid tumors became even more pronounced when these animals were crossed onto a p53 À/À background; nevertheless, Brca1
Tr/Tr ;p53 À/À mice developed tumors significantly faster than the p53 single knockouts. Similarly, Cressman et al. 1999 described three Brca1
D223À763/D223À763
;p53 À/À animals that succumbed to lymphomas. Finally, heterozygous p53 mutations introduced in mice harboring two Brca1 D11 alleles gave rise to mammary tumors in most of the animals produced, although also here lymphomas were observed . For Brca2, all three models that enabled survival of animals showed increased tumorigenesis in the absence of p53 mutations (Connor et al., 1997; Friedman et al., 1998; McAllister et al., 2002) . However, the Brca2 models displayed a strong bias towards developing thymic lymphomas. In conclusion, while these data clearly demonstrate tumor suppressor activities for Brca1 and Brca2, the utility of these models to investigate properties of human breast cancer is limited because of the low incidence of mammary carcinomas.
Conditional Brca1 and Brca2 mutants
Besides embryonic lethality and development of nonepithelial tumors, another important limitation of conventional Brca1 and Brca2 homozygous mutants is that they cannot model development of sporadic cancer, which arises amidst a genetically 'normal' background. To overcome these limitations, conditional mutagenesis strategies have been developed, which rely on Cre recombinase that catalyzes specific genetic deletion of genomic regions flanked by loxP recombination sites (Jonkers and Berns, 2002) . These recombination sites are inserted in non-coding sequences to ensure that expression of the gene is not disrupted prior to Cre-mediated recombination. Introduction of Cre recombinase into these conditional mouse mutants -via intercrosses with Cre transgenic mice or via somatic delivery -results in tissue-specific and/ or time-controlled inactivation of conditional tumor suppressor genes.
Targeting Cre expression to mammary epithelium Several promoters have been used to achieve mammary specific Cre expression, all with their own advantages and disadvantages. Wagner and co-workers published the creation of transgenic mice expressing Cre under the control of the whey acidic protein (WAP) promoter as well as the mouse mammary tumor virus long terminal repeat (MMTV) promoter (Wagner et al., 1997) , whereas Selbert et al. (1998) chose the ovine b-lactoglobulin promoter to drive Cre expression. An important limitation of these three mammary glandspecific promoters is that their activity is strongly influenced by steroid hormones. Furthermore, models employing the WAP-Cre and MMTV-Cre promoters often require one or even multiple rounds of pregnancy and lactation for effective induction of mammary tumor formation. To overcome these limitations, we created a transgenic line expressing Cre under the control of the cytokeratin-14 (K14) promoter (Jonkers et al., 2001) . Besides K14-Cre expression in salivary glands and skin, stochastic Cre-recombinase activity was found both in luminal epithelial cells and in myoepithelial cells of virgin mammary glands, suggesting that K14-Cre is expressed in both cell types or in a common progenitor. The latter hypothesis is supported by the observation that K14 is expressed in Lin
þ mammary progenitor cells or CD24 med CD49f high mammary repopulating unit (MRU) cells . The stochastic activity of K14-Cre results in Cre-mediated gene switching in only a small fraction of mammary epithelial cells. While this trait is advantageous for sporadic tumor development, it precludes assessment of direct consequences of Brca loss-of-function.
Conditional Brca1 and Brca2 alleles
Three different conditional Brca1 alleles have been generated to date: Brca1 F5-6 (Mak et al., 2000) , Brca1
Co (Xu et al., 1999a) and Brca1 F5-13 (Liu et al., manuscript in preparation; see Figure 1 ). Cre-mediated deletion of exons 5-6 or exons 5-13 from the Brca1 F5-6 or Brca1 F5-13 allele, respectively, induces a frameshift mutation that abrogates production of all three splice products (full-length Brca1, Brca1-D11 and the putative Brca1-IRIS). In contrast, deletion of exon 11 of the Brca1
Co allele results in a hypomorphic mutation that still allows for expression of Brca1-D11. For Brca2, four different conditional alleles have been published to date (Figure 2 ). Of these, the Brca2 F9-10 and Brca2 F3-4 alleles encode -upon Cre-mediated switching -truncated transcripts that are susceptible to nonsense-mediated mRNA decay (Ludwig et al., 2001b; Cheung et al., 2002) . Although the Brca2 F11 allele results in an in-frame deletion after Cre expression, early embryonic lethality of animals homozygous for the Brca2 D11 allele suggests that also this allele is a functional null (Jonkers et al., 2001 ). In contrast, Cre-mediated deletion of the Brca2 F27 allele did not result in embryonic lethality of homozygous mutants, despite the fact that the BRCA2 C-terminal domain encoded by exon 27 contains a nuclear localization signal, interacts with RAD51 in a CDKdependent manner, and is required for maintaining genomic stability after DNA damage (McAllister et al., 2002; Esashi et al., 2005) .
Mammary development in conditional Brca1/2 mutants To achieve mammary gland-specific inactivation of Brca1, Xu et al. (1999a) and with WAP-Cre;Brca2 F9-10/F9-10 animals, in which mammary gland development or involution appeared to be unaffected (Cheung et al., 2004) . However, no firm conclusions can be drawn from the latter study, since Cheung et al. did not demonstrate the existence of Brca2-deficient mammary epithelial cells with both Brca2 F9-10/F9-10 alleles recombined.
Mammary tumorigenesis in conditional Brca1 mutants
With the aim of creating a mouse model for breast cancer, MMTV-Cre;Brca1 Co/11À or WAP-Cre;Brca1
Co/11À female mice were continuously mated to induce sustained high-level expression of Cre. Some of the females indeed developed mammary tumors of diverse types, albeit with long latency (Xu et al., 1999a) . This model was subsequently improved by introduction of a single p53 null allele, yielding MMTV-Cre;Brca1 Co/Co ; p53 þ /À mice, which developed mammary tumors with reduced latency (Brodie et al., 2001) . Follow-up studies showed that this model mimicked several aspects of human BRCA1-associated carcinogenesis. Tumors were ERa-negative and displayed gross genomic instability as shown by comparative genomic hybridization (CGH) and spectral karyotyping (SKY) (Weaver et al., 2002) . Tumorigenesis in the MMTV-Cre;Brca1
Co/Co ;p53 þ /À model appeared to be critically dependent on abrogation of p53 function, since most tumors showed loss of the wildtype p53 allele (Brodie et al., 2001) . This is similar to the human situation where aberrant p53 signaling was more commonly found in BRCA1-associated breast cancers, compared to sporadic tumors (Crook et al., 1997) . Cooperation between p53 and Brca1 in mammary tumorigenesis was also demonstrated in a K14-Cre; Brca1 F5-13/F5-13 ;p53 F2-10/F2-10 mouse model with tissuespecific inactivation of both Brca1 and p53 (Liu et al., manuscript in preparation female mice, which, upon continuous mating to induce Cre expression, succumbed to nonmetastatic mammary carcinomas or adenosquamous carcinomas after a relatively long latency of B1.4 years. The tumors displayed aneuploidy and chromosomal aberrations, were ErbB2/neu-negative and usually ERaand cyclin D1-positive. Also MMTV-Cre;Brca2 F9-10/F9-10 animals developed mammary carcinomas after long latency periods of B1.6 years (Cheung et al., 2004) . This latency was significantly reduced in a p53 heterozygous background. Although there was a difference in tumor latency between MMTV-Cre;Brca2 F9-10/F9-10 ;p53
þ /À mice and MMTV-Cre;Brca2 F9-10/ þ ;p53 þ /À or p53 þ /À animals, the shift in tumor spectrum was the most striking effect of mammary gland-specific Brca2 inactivation in p53 heterozygous mice. Combined tissue-specific inactivation of both Brca2 and p53, on the other hand, resulted in highly efficient mammary tumor formation in K14-Cre;Brca2 ;p53 F2-10/F2-10 female mice (Jonkers et al., 2001) . A control group of K14-Cre;Brca2 F11/ þ ; p53 F2-10;F2-10 females showed a much longer median tumor latency (10 instead of 6 months), demonstrating that Brca2 and p53 loss-of-function have a synergistic effect on mammary tumorigenesis.
Conditional Brca1/2 mutation in other tissues
Since cancer predisposition of human BRCA1/2-mutation carriers primarily concerns breast cancer, research efforts have primarily focused on modeling this cancer type in Brca1/2 mutant mice. While the reason for this biased tumor spectrum is not understood, it is important to know whether the BRCA gene products exhibit tumor suppression functions in other tissues as well.
T-cell-specific deletion of Brca1 in Lck-Cre;Brca1
F5-6/F5-6 mice showed that thymocyte development, but not Tcell receptor recombination, is dependent on Brca1 function. Concomitant p53 abrogation or overexpression of the apoptosis inhibitor Bcl-2 rescued thymocyte survival and development (Mak et al., 2000) . Similar experiments using Lck-Cre;Brca2 F9-10/F9-10 mice did not show any changes in thymocyte cellularity or composition, although in vitro experiments showed increased apoptosis and genomic instability in both Brca1-and Brca2-deficient thymocytes (Cheung et al., 2002) . In line with the lymphoma predisposition of hypomorphic Brca2 mutants, a small acceleration of T-cell lymphomagenesis was reported for Lck-Cre;Brca2 F9-10/F9-10 ; p53 À/À mice, compared to Lck-Cre;p53 À/À control animals. Brca1 and Brca2 also have tumor suppressor activity in skin epithelium. K5-Cre;Brca1
Co/11À mice -in which Cre expression from a bovine cytokeratin-5 promoter induces recombination in, for example, the basal cell layer of the epidermis, mammary myoepithelium and oral cavity -develop squamous cell carcinomas (Berton et al., 2003) . Thus, Brca1 functions as a tumor suppressor in other epithelial tissues besides mammary gland. Interestingly, E2F1 overexpression in these animals dramatically accelerated skin tumor development, suggesting cooperation between the Rb-E2F1 pathway and Brca1 in tumorigenesis. Similar cooperation in skin tumorigenesis was found between Brca1 and p53 (Liu et al., manuscript in preparation) and between Brca2 and p53 (Jonkers et al., 2001) . The latter observation indicates that also Brca2 has tumor suppressor activity in skin epithelium.
Tumor suppressor activity of Brca1 and Brca2 in yet other tissues has not been convincingly documented to date. However, broad tumor suppressor activity of Brca1 might be suggested by the fact that Brca1
Tr/Tr mice developed, in addition to mammary tumors and lymphomas, tumors in many other organs such as lung, liver, uterus and colon (Ludwig et al., 2001a) . From a clinical perspective, it would be especially relevant to know whether ovarian-specific Brca inactivation would lead to tumors that resemble human BRCA-associated ovarian cancer. In conclusion, despite the tissue bias of human BRCA-associated cancers, Brca1 and Brca2 may have tumor suppressor activity in multiple mouse tissues, suggesting that the tumor spectrum seen in human BRCA-mutation carriers is not due to cell-type specific tumor suppression.
Genetic interactions in development and tumorigenesis
BRCA1 and BRCA2 are unusual tumor suppressors in that they are essential for normal cell survival, yet their inactivation seems pivotal for cancer development in BRCA-mutation carriers. These paradoxical observations suggest that BRCA-associated tumorigenesis might be fostered by (tissue-specific) environmental and/or genetic factors that somehow alleviate BRCAassociated growth suppression.
Genetic interactions with the p53 pathway
It has long been hypothesized that genetic interaction between BRCA1/2 and the p53 pathway results from the DNA damage that accumulates in repair-deficient BRCA-mutated cells. DSBs in these cells would trigger a p53-mediated cell cycle checkpoint that could be alleviated by, for example, mutation of p53 or its downstream target p21. This concept is supported by the observation that inactivation of p53 or p21 results in a prolonged survival of Brca-deficient embryos Ludwig et al., 1997) . Another interesting hypothesis for how p53 mutations might cooperate with BRCA deficiency relates to the recent appreciation of the potential role of tetraploid cells in tumorigenesis (Fujiwara et al., 2005) . Tetraploid cells that were obtained through induction of endoreduplication via a transient block in cytokinesis, were found to be dependent on p53 dysfunction for survival. These cells were genetically unstable and tumorigenic, properties that were not displayed by isogenic diploid cells. Interestingly, it was recently shown that Brca2 deficient cells undergo abnormal cytokinesis (Daniels et al., 2004) , and indeed knockdown of BRCA1 caused accumulation of multinucleated cells (Bae et al., 2005) . It is thus conceivable that BRCA-deficiency may foster the generation of endoreduplicated cells that require dysfunctional p53 for survival.
Genetic interaction between BRCA1/2 and the p53 pathway is supported by a large body of data. For example, p53 mutation is more often observed in BRCA-associated tumors than in sporadic cancers (Crook et al., 1997) , and BRCA1/2 tumors showed common changes at p53 codons that are not mutation hotspots (Smith et al., 1999; Greenblatt et al., 2001 ). As mentioned before, studies in mouse models have documented cooperation between loss of p53 and inactivation of Brca1 or Brca2 in tumorigenesis, although the exact nature of this cooperation remains unclear. However, p53 mutation is not sufficient for complete reversion of Brca-associated growth arrest, given the incomplete rescue of embryonic lethality and proliferation defects of cultured embryonic fibroblasts (Shen et al., 1998) . Taken together, these data suggest that abrogation of the p53 pathway is necessary but not sufficient for survival of BRCA-deficient cells.
Other genetic interactions
Besides p53, also other cell-cycle checkpoint and DNA damage response factors have been found to modulate phenotypes in Brca-deficient animals. Lee et al. (1999) provided evidence that inactivation of the spindle assembly checkpoint may be involved in Brca2-associated tumorigenesis. Following the observation that lymphomas arising from Brca2
Tr/Tr mice contain mutations in the spindle checkpoint genes Bub1 and Mad3L, it was shown that dominant-negative Bub1 rescues the proliferation defect of Brca2
Tr/Tr embryonic fibroblasts. However, direct cooperation between mutated spindle checkpoint genes and BRCA2 inactivation in tumorigenesis remains to be established.
More clear are the genetic interactions between Brca1 and Chk2, which have been documented in several Brca1 models. Chk2 deficiency was found to restore T-lymphocyte cellularity and development in LckCre;Brca1 F5-6/F5-6 ;Chk2
À/À mice and to promote mammary tumor formation in WAP-Cre;Brca1 F5-6/F5-6 ;Chk2 mutants was rescued in a Chk2-deficient or in an Atm-haploinsufficient background (Cao et al., 2006) . Together, these data suggest that loss-of-function of either Atm or Chk2 can substitute for p53 inactivation in Brca1-associated embryonic lethality and tumorigenesis, thus providing strong evidence for the activation of the Atm-Chk2-p53 DNA damage response pathway in Brca1-deficient cells. Activation of this pathway by DSBs leads to p53-induced cell cycle arrest, senescence and apoptosis (Kastan and Bartek, 2004) . Chk2 activates p53 through phosphorylation, and may therefore not only function as an 'amplifier' of DNA damage response but also as a tumor suppressor. Indeed, heterozygous germline CHK2 mutations were found in families with non-p53 Li-Fraumeni syndrome (Bell et al., 1999) . In addition, the CHK2*1100delC variant, encoding an unstable truncated protein lacking the kinase domain, was identified as a low-penetrance breast cancer susceptibility gene in noncarriers of BRCA1 or BRCA2 mutations (Meijers-Heijboer et al., 2002) .
GADD45a is a growth arrest-and DNA damageinducible gene, and a transcriptional target of BRCA1 (Harkin et al., 1999) . Since also Gadd45A-deficient mouse embryonic fibroblasts exhibited centrosome amplification (Hollander et al., 1999) , genetic interactions between Brca1 and Gadd45 were studied in Brca1 D11/D11 ;Gadd45a À/À mice. Compound mutant embryos died at E9.5-10.5, exhibiting exencephaly and high rates of apoptosis, probably due to activation of p53 as a result from increased genetic instability (Wang et al., 2004b) . The relevance of this interaction for BRCA1-associated tumor formation is still unclear.
Applications of current Brca1 and Brca2 mouse models

Validation studies
The development of mice with mammary gland-specific deletion of Brca1 or Brca2 has not only improved our understanding of BRCA-associated breast cancer in humans, but also provided tools that can be used to test novel therapeutic intervention and tumor prevention strategies. To this end, it is important to validate the different mouse models with respect to the human disease. Ideally, validation of the mouse models should not only include comparative histopathology and cross-species comparison of gene expression profiles and molecular genetic alterations, but also therapeutic benchmarking by testing responses of mouse mammary tumors to conventional chemotherapy and radiotherapy. Although not necessarily all human aspects need to be recapitulated in one mouse model for it to be useful, careful assessment of all differences and similarities is important for correct interpretation of results obtained with the mouse model.
Most Brca1 and Brca2 mouse mammary tumor models generated to date have been validated to only a limited extent (Table 1) . In general, they show a relatively high incidence of mammary carcinomas, have deregulated p53 pathways and show genetic instability in the resulting tumor cells. Several mouse models, especially the Brca2 mammary tumor models, developed mammary tumors with histopathological features that were rather different from their human counterparts. Whether this is reflective of a difference in cell-of-origin or a more general difference between both species remains unclear. Cross-species comparison of gene expression data from mammary tumors of the K14-Cre;Brca1 F5-13/F5-13 ;p53
F2-10/F2-10 model revealed gene expression signatures with features of basal-like breast cancers and strong resemblance to human BRCA1-mutated breast cancers (Liu et al., manuscript in preparation) . Analysis of DNA copy number alterations in mammary tumors from the MMTV-Cre;Brca1
Co/D11 , WAP-Cre;Brca1
Co/D11 and WAP-Cre;Brca1
Co/D11
;p53
þ /À models by CGH and SKY revealed a pattern of chromosomal gains and losses that resembled the pattern in human breast cancers, although a cross-species comparison with data from human BRCA1-associated tumors was not performed (Weaver et al., 2002) . With the most advanced models currently mimicking several aspects of human BRCA-associated tumorigenesis, the time seems ripe to start using these mouse models for addressing clinically relevant questions. In fact, the first translational studies have already been reported.
Hormone dependency of BRCA1-associated tumorigenesis Disruption of ubiquitously expressed BRCA genes leads to a tumor spectrum that shows specificity towards steroid hormone-responsive target organs, such as the mammary glands, ovaries and prostate. Both BRCA1 and BRCA2 expression are, albeit indirectly, responsive to estrogen levels (Spillman and Bowcock, 1996) , and conversely, BRCA1 was found to inhibit ERa mediated signaling (Fan et al., 1999; Xu et al., 2005) . Therefore, it was suggested that estrogen signaling might be important in BRCA-associated tumorigenesis, thus providing a possible explanation for the observed tissue specificity. In support of this, it has been shown that premenopausal oophorectomy exerts an B50% reduction of the risk of breast cancer in BRCA1 mutation carriers (Rebbeck et al., 1999) . Also, adjuvant antiestrogenic tamoxifen therapy resulted in a decreased risk of second primary carcinomas and an improved overall survival of BRCA mutation carriers (Metcalfe et al., 2004; Noruzinia et al., 2005) .
The mechanism by which oophorectomy exerts a protective effect remains to be elucidated. Paradoxically, BRCA1 associated tumors express ERa less often than sporadic tumors (Phillips, 2000) . Since certain effects of estrogen on normal mammary epithelial proliferation and morphogenesis are mediated through paracrine mechanisms (Mallepell et al., 2006) , it is conceivable that similar paracrine signals from surrounding ERapositive cells might stimulate proliferation of ERanegative BRCA1-deficient tumor cells. Alternatively, tumors in which BRCA1 loss-of-function resulted in loss of negative control on estrogen signaling, may require less ERa expression (beneath the detection limit in histochemical assays) for stimulation by estrogen. A third possibility is that ERa expression is expressed during initial stages of BRCA1-associated tumorigenesis but is lost in the process of tumor progression.
To gain more insight in the role of estrogen signaling in BRCA-associated tumorigenesis, the MMTV-Cre; Brca1
Co/Co ;p53
þ /À mouse model developed by the group of Deng, has been used to study the effects of interventions in this pathway (Bachelier et al., 2005) . Concurrent with the human situation, there was a significant protective effect of oophorectomy on the occurrence of mammary cancer in older animals. Although the mechanism underlying this effect remains unclear, it was shown that mammary glands of oophorectomized mice underwent regression. Of note, oophorectomy studies in the MMTV-Cre;Brca1
Co/Co ; p53 þ /À model are compromised by the fact that extent of MMTV-Cre mediated Brca1 mutation -and thus the incidence and multiplicity of mammary tumors -may be influenced by levels of steroid hormones. Hence, reduced mammary tumor formation in oophorectomized MMTV-Cre;Brca1
females might be an artifact, caused by decreased Cre activity. Hormone dependency of MMTV-Cre might also explain the unexpected results from tamoxifen treatment studies in the MMTV-Cre;Brca1 Co/Co ;p53 þ /À model, showing accelerated development of mammary tumors in tamoxifen-treated female mice (Jones et al., 2005) . While the experiments performed in this study suggest that loss of full-length Brca1 expression alters the agonist/antagonist activity of tamoxifen to the extent that the agonistic function becomes more pronounced, firm conclusions can only be drawn when these results are confirmed in a different model.
Despite the technical limitations associated with the MMTV-Cre;Brca1
Co/Co ;p53 þ /À model, the studies of Bachelier et al. and Jones et al. provide a proofof-concept for the utility of mouse Brca1/2 mammary tumor models to investigate clinically relevant questions. This type of research will no doubt help us to (2000) and Lakhani et al. (2002) . b It is unclear whether BRCA2 tumors show more p53 mutations, compared to sporadic tumors.
However, since p53 mutations are found in 40-50% of BRCA2 tumors, we have scored p53 mutations in the mouse Brca2 models as being in concordance with the human condition. For each property, a '+' indicates similarity to the human situation, where as a '-' indicates lack of similarity. '+/-' symbols indicate heterogeneity of the factor involved, and 'ND' indicates no information has been reported.
Mouse models of BRCA1/2 deficiency B Evers and J Jonkers address clinically relevant questions and provide knowledge that can subsequently be translated into clinical practice.
Targeting BRCA-deficient cells and tumors Another example that highlights the value of conditional Brca1/2 mammary tumor models for preclinical studies concerns the research on antitumoral and tumor preventive activities of chemical inhibitors of poly-(ADP-ribose)-polymerase-1 (PARP1). PARP1 deficiency results in increased Rad51 foci formation and sister chromatid exchanges, but does not affect DSB repair via HR (Schultz et al., 2003) . Based on these observations, it was hypothesized that inhibition of PARP1 activity in BRCA-deficient cells with defective HR would result in cytotoxicity due to rapid accumulation of DNA damage. Since DNA lesions in BRCA-proficient cells can be repaired by HR, PARP1 inhibition may have a wide therapeutic window. Indeed, several groups showed that chemical inhibitors of PARP1 activity increased DNA damage and caused specific killing of cells with impaired BRCA1 or BRCA2 function (Bryant et al., 2005; Farmer et al., 2005) . In both studies, treatment with PARP1 inhibitors induced regression of Brca2-deficient tumors in transplantation models. To further validate this approach to targeting BRCAdeficient cells, a small intestine-specific inducible Cre line (Ah-Cre) was crossed to mice carrying conditional Brca2 F9-10 alleles as well as a reporter for Cre-mediated recombination, ROSA26R (Soriano, 1999; Hay et al., 2005b) . Subsequent treatment of mice with PARP1 inhibitors resulted in depletion of reporter-positive cells specifically in Ah-Cre;Brca2 F9-10/F9-10 ;Rosa26R intestines but not in Ah-Cre;Brca2 F9-10/ þ ;Rosa26R intestines, suggesting specific depletion of Brca2-deficient cells (Hay et al., 2005a) . These findings pave the way for extending the application of PARP1 inhibitors from therapeutic towards prophylactic settings. If loss of BRCA function is an early event in mammary tumor formation in human mutation carriers, such cells might be specifically depleted by PARP1 inhibition, even before turning malignant.
The potential use of PARP1 inhibitors for targeting BRCA-deficient or 'BRCA-like' tumors with defective HR is exciting and, clearly, the current Brca1/2 mammary tumor models are valuable tools for studying both therapeutic and prophylactic applications of PARP1 inhibitors in more detail. Also, evaluation of combination therapies in these mouse models can provide important information for the clinic, where the first clinical trials using PARP1 inhibitors have already started.
Conclusions and future perspectives
Since the discovery of BRCA1 and BRCA2, mouse models have proven of paramount importance for obtaining information on the function of these genes, both in development and tumorigenesis. Studies in conventional and conditional Brca1/2 mouse mutants have provided insight into the role of Brca1 and Brca2 in various cellular processes, and established genetic interactions with several other proteins, most notably components of the DNA damage response pathway. Tumor suppressor activity of both BRCA proteins was confirmed in several mouse models, not only in the mammary gland but also in skin and lymphoid compartments. Nevertheless, the tumor spectrum of the mouse models parallels the human tumor spectrum at least to some extent, since a clear bias towards mammary tumorigenesis is reported in conditional Brca1/2 models employing MMTV-Cre and K14-Cre, which express Cre in multiple tissues besides mammary gland.
Other features that are recapitulated by at least some of the mouse models include tumor histology and aneuploidy.
Despite our increased understanding of the function of BRCA1 and BRCA2, several important questions remain yet to be resolved. The intriguing observation that BRCA inactivation induces growth arrest in normal cells, yet promotes tumor formation in mutation carriers, strongly suggests the presence of secondary suppressor mutations that may overcome such an arrest during BRCA-associated tumorigenesis. Also stromal factors might foster in situ survival of BRCA-deficient mammary tumor cells. Cancer-associated fibroblasts contribute to various stages of tumor growth (Kalluri and Zeisberg, 2006) , and also immune cells can support cancer development (de Visser et al., 2006) . Clearly, mouse models are key to investigating these complex tumor-host interactions in the context of BRCA-associated tumor formation.
Another unresolved aspect of BRCA-associated tumorigenesis concerns gender bias and tissue-specificity of the disease. This tissue specificity might be caused by redundant pathways, specifically absent in mammary epithelium, that could mask BRCA-associated phenotypes in other tissues. However, the embryonic lethality of Brca1/2 homozygous mouse mutants argues against the existence of pathways that are functionally redundant with BRCA1 or BRCA2 in cell proliferation. It has therefore been proposed that the observed bias may be explained by cell type-specific and/or environmentdependent survival of BRCA-deficient mammary and ovarian epithelial cells (Elledge and Amon, 2002) . Since the spectrum of BRCA-related cancers is biased towards organs that are targets of estrogen, it is conceivable that survival factors in the form of hormones may have a protective effect on BRCA-deficient cells. These and other possibilities may be effectively explored in Brca1 and Brca2 mouse models.
Future research is also expected to provide more insight into the genotype-phenotype correlations that have emerged from the analysis of the various Brca1 and Brca2 mutants. It is conceivable that at least some of these correlations may also be of relevance for pathogenesis and clinical responses of BRCA-associated tumors in human mutation carriers. Phenotypic analysis of mice engineered to express one or more of the observed Brca1 splice variants may shed light on the specific functions of the different Brca1 protein products. Similarly, mouse Brca1 and Brca2 mutants with specific amino acid changes may uncover functions of specific protein domains or phosphorylation sites. One such mutant, Brca1
S971A
, encoding a Brca1 protein with an inactivated Chk2 phosphorylation site, has already been described, showing predisposition to carcinogeninduced tumorigenesis . Clinically more relevant would be the generation of mouse mutants with truncation mutations mimicking human BRCA1/2 germline mutations. These models may be used to assess tumor predisposition and clinical responses of known disease-associated mutations. Recently developed 'humanized' mouse models carrying human BRCA1 BAC transgenes (Yang et al., 2003) or oligo targeting techniques that allow targeted insertion of subtle point mutations and small insertions into mouse embryonic stem cells (Dekker et al., 2003 (Dekker et al., , 2006 are particularly suitable for such allelic series of Brca1/2 mutations.
Existing as well as new mouse models for BRCAassociated breast cancer -and perhaps other 'BRCAlike' tumors with impaired HR -are expected to play an increasing role in preclinical and translational research. Robust validation of the utility of mouse models for preclinical applications is important and should include cross-species comparisons of tumor characteristics and responses to chemotherapeutics. Nevertheless, the first studies with targeted therapeutics in some of the existing models have already been reported, thus sparking the hope that breast cancer patients will soon benefit from the collective research on mouse models of BRCA1 and BRCA2 deficiency.
